Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
Narayana Hrudayalaya Ltd rose 6.98% today to trade at Rs 1876. The BSE Healthcare index is up 0.58% to quote at 44910.98. The index is up 0.01 % over last one month. Among the other constituents of the index, Lincoln Pharmaceuticals Ltd increased 6.25% and Anuh Pharma Ltd added 4.78% on the day. The BSE Healthcare index went up 5.65 % over last one year compared to the 9.18% surge in benchmark SENSEX.
Narayana Hrudayalaya Ltd has added 6.81% over last one month compared to 0.01% gain in BSE Healthcare index and 0.89% rise in the SENSEX. On the BSE, 21134 shares were traded in the counter so far compared with average daily volumes of 35081 shares in the past one month. The stock hit a record high of Rs 2371.6 on 27 Jun 2025. The stock hit a 52-week low of Rs 1238.45 on 28 Nov 2024.
EBITDA fell by 14.86% to Rs 32.66 crore in Q2 FY26 from Rs 38.35 crore in Q2 FY25.
Profit before tax in Q2 FY26 stood at Rs 28.81 crore, down by 17.17% from Rs 34.78 crore recorded in Q2 FY25.
Lincoln Pharmaceuticals stated that the company is targeting a revenue of Rs 1,000 crore within the next three years, driven by business expansion into high-value product lines and entry into new markets. This goal is part of a broader strategy to achieve a 15-18% annual growth rate, driven by strong performance in the cardiac, diabetic, dermatology, and ENT segments.
Mahendra Patel, managing director, Lincoln Pharmaceuticals, said: 'We are pleased to report another strong quarter, reflecting our continued focus on sustainable growth and value creation.
Our growth momentum is supported by expansion into high-value therapeutic segments such as cardiac, diabetic, dermatology, and ENT, along with new product introductions and entry into emerging markets.
The commissioning of our Bulk Drug Manufacturing Plant and progress at our Cephalosporin facility further strengthen our backward integration and export capabilities.
With a debt-free balance sheet, we are well positioned to deliver sustainable, profitable growth and enhance long-term shareholder value.'
Lincoln Pharmaceuticals has been manufacturing pharmaceutical formulations in the domestic market as well as exporting formulations. The company is part of the Lincoln Group, which manufactures pharmaceuticals formulations in categories such as generics, anti-malarial, anti-diabetic, gynaecology products, vitamins, minerals and anti-oxidants.